About Hariprasad Vankayalapati
Hariprasad Vankayalapati is a co-founder · chief scientific officer and director at Biolexis Therapeutics.
Hariprasad Vankayalapati first appears on SEC filings in 2022.
Experience
This experience comes from Hariprasad Vankayalapati's profile and from SEC filings. For roles taken from filings, the years are when the filings name Hariprasad Vankayalapati in the role, so the role may have started earlier or lasted longer.
Biolexis Therapeutics Inc. Current
Co-founder · Chief Scientific Officer and director
2022 – Present · Lehi, UT
Develops oral drug candidates for people with obesity and type 2 diabetes.
OI
Oncolexis Therapeutics, Inc.
Chief Scientific Officer
2021 – 2024
AP
Arrien Pharmaceuticals
Chief Scientific Officer
2011 – 2024
HI
Huntsman Cancer Institute
Associate Professor of Medicinal Chemistry
2009 – 2022
TH
TGen - an Affiliate of City of Hope
Associate Professor of Medicinal Chemistry
2017 – 2019
AC
Alveus Pharmaceuticals (CRO Company)
Chief Scientific Officer/Director of Medicinal Chemistry
2009 – 2016
SP
SuperGen Inc. (Otsuka/Astex Pharmaceuticals)
Scientific Advisor of Medicinal Chemistry (2009 – 2010)
Chief Scientist, Medicinal Chemistry (2009)
2009 – 2010
SA
SuperGen/Astex
Chief Scientist/Director of Medicinal Chemistry
2006 – 2009
MI
Montigen Pharmaceuticals Inc.
Director of Medicinal Chemistry
2003 – 2006
NI
NeuroPro Technologies Inc.
Director of Medicinal Chemistry
2003
AA
Arizona Cancer Center, University of Arizona
Associate Research Scientist/Core facility Co-Director
2000 – 2003
RI
Ranbaxy Laboratories Ltd. New Delhi, India
Research Scientist
1996 – 1998
Key Colleagues at Startups
The people Hariprasad Vankayalapati works with at each company, as listed on that company's latest Form D.
Biolexis Therapeutics Inc. · Form D, Jun 3, 2026
Tyler Hartmann
President
JC
James Clarke
Director
AS
Anthony Steve
Director
David Bearss
Co-founder · Chairman